Here's How The FDA's Temporary Peptide Compounding Policy Impacts Access, Costs And Safety

Peptides are everywhere right now. Influencers swear by them for faster healing, glowing skin and weight loss and telehealth companies are lining up to sell them. Now, as a result of a new federal move, some of them may become easier to get.

On Oct. 15, the FDA sent an “interim access policy for compounding using certain peptides” to the White House for review, Reuters reported. If it moves forward, this temporary peptide compounding policy could let pharmacies make certain unapproved peptides, including the popular BPC-157, while the agency works on permanent rules.

However, easier access is not the same as proven safety. Here’s what medical experts want you to know before you try peptide therapy.

What exactly are peptides? (And why is everyone talking about them?)

At their core, peptides are short chains of amino acids, the building blocks of protein. Inside the body, they act as messengers that help control things like appetite, healing and hormone release. Some peptides are FDA-approved medications. For example, insulin is a peptide, and so is semaglutide, the active ingredient in Ozempic and Wegovy.

However, many of the peptides trending online are a different story. BPC-157, nicknamed “Wolverine,” is marketed for injury recovery. Meanwhile, other peptides are sold for muscle, sleep and anti-aging. Unlike approved drugs, these have not undergone the trials the FDA requires to demonstrate a drug is safe and effective.

Danny Barnes, PharmD, BCSCP, is a board-certified sterile compounding pharmacist and president of Triangle Compounding Pharmacy. However, he said the label can hide a lot. “When someone mentions ‘peptide therapy’ online, it could be anything from these to something completely unknown that your provider has no follow-up plan for,” he told Blavity Health.

The FDA’s new proposal: A temporary pass, not a free-for-all

Normally, compounding pharmacies can only use bulk ingredients that meet strict federal criteria. In July, FDA advisers recommended adding six peptides to that list, including BPC-157, TB-500 and MOTS-c, according to Holland & Knight. Still, the vote was nonbinding. In addition, formal rulemaking could take years.

The proposed interim policy would fill that gap with “enforcement discretion.” In other words, the FDA would choose not to take action against qualifying pharmacies for a while. For example, possible conditions include state licensure, valid prescriptions and adverse event reporting, according to Buchanan Ingersoll & Rooney.

Still, that is not the same as approval. “Just because something is under ‘enforcement discretion’ does not mean it’s FDA approved. Nor does it mean it’s safe to use,” Barnes said. “It simply means that the FDA isn’t going to focus their attention on something at the moment.”

Shawn Hamilton, MD, MBA, a board-certified internist and former regional medical director at Health Net of California, put it more bluntly. “Enforcement discretion means they have other fish to fry,” she told Blavity Health. It does not mean, she added, “that it has been studied or consistent dosing is established for these types of compounds.”

Why the FDA is proceeding with caution

FDA career staff have reportedly pushed back on the policy over patient safety. In fact, the agency has spelled out its concerns about BPC-157 before. According to the FDA, compounded BPC-157:

• “May pose risk for immunogenicity,” meaning it could trigger an immune reaction.
• Can involve “peptide-related impurities.”
• Has “no, or only limited, safety-related information” for the ways people use it.

Jason Schroder, MD, an anesthesiologist and co-founder and medical director of Craft Body Scan in Tulsa, Oklahoma, sees patients drawn in by online buzz. “If the injectable is not made properly, then there is a risk of infection due to contamination,” he told Blavity Health. “Just because there are a few good reviews doesn’t mean you know what’s in the product or how your body will react.”

Henry Legere, MD, an immunologist and chief medical officer at the wellness chain Restore Hyper Wellness, said the early research on BPC-157 is promising but limited. “Preclinical studies, primarily in animal models, have demonstrated promising effects on tendon healing, tissue repair, inflammation and blood vessel formation,” he told Blavity Health. “However, we need to distinguish promising biological mechanisms from proven clinical benefits.”

He added that feeling better isn’t the same as healing. “Pain and inflammation can improve long before a tendon, ligament, or muscle has regained its structural integrity,” he said. Moreover, “changes in compounding policy should not be interpreted as proof of safety or effectiveness.”

Of course, Black Americans have good reason to be skeptical of the medical system. Too often, doctors haven’t listened. Still, a confident influencer or a slick telehealth ad is not a substitute for evidence. That applies even more to a product labeled “research use only,” which by definition is not meant for people.

Barnes said a careful pharmacist would start with basic questions. “Is it legal to compound? Can I even use this ingredient? What will it be compounded in? Will it be sterile?” he said.

Telehealth and online sellers: Read the fine print

Many peptides sold online carry a “research use only” or “not for human consumption” label. The FDA isn’t buying it. On Aug. 24, the agency sent warning letters to four online peptide sellers. As a result, it treated their products as unapproved new drugs despite the disclaimers, according to an analysis by the law firm Sheppard.

Similarly, “Research use only websites have no standard when it comes to keeping the patient safe,” Hamilton said.

Barnes added that paperwork and a quick online visit aren’t proof of safety, either. “Certificate of analysis or telehealth does not equal FDA-approved or even prescribed to you,” he said.

Moreover, those labels may not protect sellers in court, either. C.L. Mike Schmidt is a trial attorney and partner at Schmidt & Clark, LLP, who handles product liability cases. “‘Research use only’ does not automatically shield a seller from legal responsibility, nor does it necessarily mean a product is safe for human consumption,” he told Blavity Health.

Also, be wary of any clinic that claims the FDA “endorses” peptides under this policy. It doesn’t. In addition, ask where the clinic’s pharmacy gets its ingredients. Telehealth giant Hims & Hers has already said it plans to offer peptides if regulations allow, Reuters reported. So expect a lot more marketing.

How to protect yourself if you’re exploring peptide therapy

If you’re considering peptides, then the source matters as much as the substance.

Know where your peptide is made

According to the FDA, “Compounded drugs are not FDA-approved.” Even so, the type of pharmacy makes a big difference.

• 503A compounding pharmacies make medications for individual patients with a prescription. State boards of pharmacy oversee them.
• 503B outsourcing facilities register with the FDA, follow federal manufacturing standards and get inspected by the agency.
• “Research use only” websites are neither. They aren’t pharmacies, and they don’t require a prescription.

Barnes suggests asking a pointed question: “Are they actually writing you a patient-specific prescription or just picking something off a list of peptides they have available?” Likewise, you can ask whether the pharmacy’s bulk ingredients are sourced from an FDA-registered facility and accompanied by a certificate of analysis.

Talk to a doctor you trust

A quick telehealth visit may not cover your full history. For that reason, bring peptides up with your primary care doctor, too. “Always make sure to ask your provider if a peptide is currently FDA approved and what it’s approved for,” Hamilton said.

In addition, she urges patients to know the plan. “Make sure when starting peptides you know your prescriber’s goal,” she said. “What will you use to evaluate its success or if you’re doing harm, and what is your plan if it’s not working?”

Also, ask about other options. “If patients are looking into using something new, I always ask them what they are looking to improve and what they’ve tried previously,” Schroder said. “Sometimes there can be well-researched treatments that you could consider.”

Bottom line

The FDA’s proposed peptide compounding policy could make some unapproved peptides easier to get from licensed pharmacies, but it would not make them approved or proven safe. If you’re curious about peptides, skip “research use only” products, ask hard questions about sourcing and talk to a doctor you trust.

Frequently Asked Questions

Why are peptides not FDA-approved in the USA?

Many peptides are FDA-approved, including insulin and semaglutide, but trendy wellness peptides like BPC-157 have never undergone the clinical trials the FDA requires to demonstrate a drug is safe and effective.

Can I get in trouble for buying peptides?

So far, FDA enforcement has targeted sellers, but the agency treats “research use only” peptides marketed for human use as unapproved drugs, and they carry real health risks.

Citations

Buchanan Ingersoll & Rooney. FDA peptide compounding policy: What a temporary enforcement reprieve could mean for pharmacies. Published October 14, 2026. https://www.bipc.com/fda-peptide-compounding-policy-what-a-temporary-enforcement-reprive-could-mean-for-pharmacies

Holland & Knight. FDA advisory committee endorses compounding of certain peptides. Published August 2026. https://www.hklaw.com/en/insights/publications/2026/08/fda-advisory-committee-endorses-compounding-of-certain-peptides

Mercer A. FDA balances peptide policy with enforcement against unlawful peptide sellers. Sheppard. Published September 18, 2026. https://www.sheppard.com/insights/blogs/fda-balances-peptide-policy-with-enforcement-against-unlawful-peptide-sellers

Reuters. US FDA takes step to change peptide compounding policy. Published October 15, 2026. https://www.reuters.com/legal/litigation/us-fda-takes-step-change-peptide-compounding-policy-2026-10-15/

U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Updated April 22, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

U.S. Food and Drug Administration. Compounding and the FDA: Questions and answers. Updated September 16, 2025. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers